<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2408">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05129813</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-18-MED-38</org_study_id>
    <secondary_id>3UG1DA013034-20</secondary_id>
    <nct_id>NCT05129813</nct_id>
  </id_info>
  <brief_title>Improving Treatment and Recovery Services for Individuals With Opioid Problems</brief_title>
  <official_title>Improving Treatment and Recovery Services for Individuals With Opioid Problems and Their Family Members</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Howard University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland, College Park</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unity Health Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Howard University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants include persons receiving buprenorphine treatment and Recovery Guide counseling&#xD;
      in a Federally Qualified Health Center or buprenorphine treatment by telemedicine and&#xD;
      Recovery Guide counseling in a church or faith-based community organization. Participants are&#xD;
      interviewed at the outset of treatment, after 4 to 6 weeks, and then at 10 to 12 weeks of&#xD;
      treatment. The study is an observational study aimed at evaluating the experiences and&#xD;
      response to treatment of participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants include persons receiving buprenorphine treatment and Recovery Guide counseling&#xD;
      in a Federally Qualified Health Center or buprenorphine treatment by telemedicine and&#xD;
      Recovery Guide counseling in a church or faith-based community organization. Participants are&#xD;
      interviewed at the outset of treatment, after 4 to 6 weeks, and then at 10 to 12 weeks of&#xD;
      treatment. The study is an observational study aimed at evaluating the experiences and&#xD;
      response to treatment of participants. Interviews use a semi-structured format assessing&#xD;
      current and past opioid and other substance use, adherence to buprenorphine, and experiences&#xD;
      with the counseling and other services provided.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Retention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of participants continuing to receive buprenorphine treatment at 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication adherence</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent days self-reported medication adherence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction</measure>
    <time_frame>12 weeks</time_frame>
    <description>Self-reported satisfaction with treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Self-reported opioid and other drug use</measure>
    <time_frame>12 weeks</time_frame>
    <description>Self-reported drug use</description>
  </other_outcome>
  <other_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>12 weeks</time_frame>
    <description>Self-reported health-related quality of life</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Counseling</condition>
  <arm_group>
    <arm_group_label>Buprenorphine MOUD in FQHC</arm_group_label>
    <description>Participants receiving buprenorphine treatment and Recovery Guide counseling in a Federally Qualified Health Center. Recovery Guide counseling is provided weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telemedicine Provision of Buprenorphine MOUD in a community site</arm_group_label>
    <description>Participants receiving buprenorphine treatment provided by telemedicine from a hub clinic and Recovery Guide counseling in a church or faith-based community organization. Recovery Guide counseling is provided weekly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Recovery Guide Counseling</intervention_name>
    <description>Recovery Guide Counseling is a 12-session psychoeducational and behavioral counseling intended for delivery by Peer Recovery Specialists, community health workers, or other personnel without advanced training in counseling</description>
    <arm_group_label>Buprenorphine MOUD in FQHC</arm_group_label>
    <arm_group_label>Telemedicine Provision of Buprenorphine MOUD in a community site</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Potential participants will be recruited through posters, flyers, or word-of-mouth or&#xD;
        information provided to them by neighborhood or community agencies or organizations or&#xD;
        referred by their medical provider.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Opioid use disorder&#xD;
&#xD;
          -  Initiating buprenorphine treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to understand the study protocol or assessment questions&#xD;
&#xD;
          -  Severe medical or psychiatric co-morbidity, including active psychosis, high risk for&#xD;
             suicide, or medical contraindications to buprenorphine (e.g., allergy or sensitivity&#xD;
             to buprenorphine),&#xD;
&#xD;
          -  Currently (or in the past 30 days) receiving MAT for OUD.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Schottenfeld, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Howard University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Schottenfeld, M.D.</last_name>
    <phone>202-865-6615</phone>
    <email>richard.schottenfeld@howard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Denise Scott, Ph.D.</last_name>
    <phone>202-865-2294</phone>
    <email>d_m_scott@howard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Howard University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Schottenfeld, M.D.</last_name>
      <phone>202-865-6615</phone>
      <email>richard.schottenfeld@howard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Denise Scott, Ph.D.</last_name>
      <phone>202-865-2294</phone>
      <email>d_m_scott@howard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gloria Cain, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid Use Disorder</keyword>
  <keyword>Behavioral Counseling</keyword>
  <keyword>Peer Recovery Specialist</keyword>
  <keyword>Buprenorphine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

